98%
921
2 minutes
20
Introduction: Enhanced creativity is often cited as an effect of microdosing (taking repeated low doses of a psychedelic drug). There have been recent efforts to validate the reported effects of microdosing, however creativity remains a difficult construct to quantify.
Objectives: The current study aimed to assess microdosing's effects on creativity using a multimodal battery of tests as part of a randomised controlled trial of microdosing lysergic acid diethylamide (LSD).
Methods: Eighty healthy adult males were given 10 µg doses of LSD or placebo every third day for six weeks (14 total doses). Creativity tasks were administered at a drug-free baseline session, at a first dosing session during the acute phase of the drug's effects, and in a drug-free final session following the six-week microdosing regimen. Creativity tasks were the Alternate Uses Test (AUT), Remote Associates Task (RAT), Consensual Assessment Technique (CAT), and an Everyday Problem-Solving Questionnaire (EPSQ).
Results: No effect of drug by time was found on the AUT, RAT, CAT, or EPSQ. Baseline vocabulary skill had a significant effect on AUT and RAT scores.
Conclusions: Despite participants reporting feeling more creative on dose days, objective measurement found no acute or durable effects of the microdosing protocol on creativity. Possible explanations of these null findings are that laboratory testing conditions may negatively affect ability to detect naturalistic differences in creative performance, the tests available do not capture the facets of creativity that are anecdotally affected by microdosing, or that reported enhancements of creativity are placebo effects.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775047 | PMC |
http://dx.doi.org/10.1007/s00213-024-06680-z | DOI Listing |
Neuropharmacology
August 2025
Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, 22 Park Avenue, Grafton, Auckland, 1023, New Zealand. Electronic address:
Expectations can impact antidepressant treatment and psychedelic therapy, often enhancing placebo effects and influencing outcomes. However, research in this context is lacking. Our study explored the expectations of participants with major depressive disorder (MDD) before microdosing lysergic acid diethylamide (LSD) in an open-label trial.
View Article and Find Full Text PDFCureus
July 2025
Medicine, Avalon University School of Medicine, Willemstad, CUW.
Lysergic acid diethylamide (LSD) is an ergot-derived psychedelic agent that produces perceptual and psychic effects of heightened sensations by acting on the dopaminergic, adrenergic, and serotonergic pathways in the brain and periphery, with 5-hydroxytryptamine 2A (5-HT2A) as the primary target molecule. Its action on these receptors in the central nervous system is comparatively well studied with respect to the psychedelic effects; however, there is speculative evidence of cardioprotective effects in the current literature attributed to the usage of this substance, even though acute ingestion causes tachycardia and hypertension, just like other psychedelics. Larger recreational doses of the drug can lead to cardiovascular and cerebrovascular incidents, but chronic peripheral antagonism of 5-HT2A receptors by the drug reduces atherosclerotic and thrombotic processes due to a reduction in platelet aggregation and vascular smooth muscle cell proliferation.
View Article and Find Full Text PDFJ Eat Disord
July 2025
Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, University of Sydney, Sydney, NSW, 2050, Australia.
Background: There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating Disorders ("MED-FED") survey investigated the lived experience of adults with EDs regarding their prescription and non-prescription drugs use. Psychedelic drugs were highly rated in this survey for their impact on ED symptoms and general mental health.
View Article and Find Full Text PDFbioRxiv
June 2025
Brigham Young University, Department of Cell Biology and Physiology, Provo, UT 84602 USA.
Psychedelics are emerging as a promising treatment option for a range of neuropsychiatric disorders, including substance use disorders. One potential mechanism underlying their therapeutic benefits may involve a reversal of maladaptive plasticity induced by drug exposure. Here, we identify physiological, behavioral, and epigenetic impacts of lysergic acid diethylamide (LSD) on morphine-treated male and female mice.
View Article and Find Full Text PDFVet Med Sci
July 2025
Asociación Científica Psicodélica, Canary Islands, Las Palmas de Gran Canaria, Spain.
This pilot study explored the potential of microdosing 1-cyclopropionyl-d-lysergic acid diethylamide (1cp-LSD) to treat canine anxiety. A single-case study was conducted on a 13-year-old female dog with severe separation anxiety, who was treated with 5 µg of 1cp-LSD every 3 days for a month. Anxiety was assessed before, after, and 1 month following treatment using a validated questionnaire.
View Article and Find Full Text PDF